Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile -Associated Diarrhea

Journal of Medicinal Chemistry

Volumn 58, Issue 12, 2015, Pages 5137-5142

  Yin, Ning ^a   Li, Jing ^a   He, Yong ^a   Herradura, Prudencio ^a   Pearson, Andre ^a   Mesleh, Michael F ^a   Mascio, Carmela T ^a   Howland, Karen ^a   Steenbergen, Judith ^a   Thorne, Grace M ^a   Citron, Diane ^b   Van Praagh, Andrew D G ^a   Mortin, Lawrence I ^a   Keith, Dennis ^a   Silverman, Jared ^a   Metcalf, Chester ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b R M ALDEN RESEARCH LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPEPTIDE; DAPTOMYCIN; LIPOPEPTIDE; SUROTOMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; IN VITRO STUDY; LIPOPHILICITY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; STRUCTURE ACTIVITY RELATION; SYRIAN HAMSTER; ANIMAL; CHEMISTRY; COMPLICATION; DIARRHEA; DRUG EFFECTS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HAMSTER; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CRICETINAE; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; LIPOPEPTIDES; MALE; MICROBIAL SENSITIVITY TESTS; PEPTIDES, CYCLIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84933039961     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00366     Document Type: Article

References (22)

1. Lessa, F. C.; Gould, C. V.; McDonald, L. C. Current status of Clostridium difficile infection epidemiology Clin. Infect. Dis. 2012, 55 (Suppl 2) S65-S70
2. Miller, B. A.; Chen, L. F.; Sexton, D. J.; Anderson, D. J. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile Infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals Infect. Control Hosp. Epidemiol. 2011, 32 (4) 387-390
3. Tonna, I.; Welsby, P. D. Pathogenesis and treatment of Clostridium difficile infection Postgrad. Med. J. 2005, 81 (956) 367-369
4. Dethlefsen, L.; Huse, S.; Sogin, M. L.; Relman, D. A. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing PLoS Biol. 2008, 6 (11) e280
5. Surawicz, C. M.; Brandt, L. J.; Binion, D. G.; Ananthakrishnan, A. N.; Curry, S. R.; Gilligan, P. H.; McFarland, L. V.; Mellow, M.; Zuckerbraun, B. S. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections Am. J. Gastroenterol. 2013, 108 (4) 478-498
6. Dubberke, E. R.; Olsen, M. A. Burden of Clostridium difficile on the healthcare system Clin. Infect. Dis. 2012, 55 (Suppl 2) S88-S92
7. Chang, J. Y.; Antonopoulos, D. A.; Kalra, A.; Tonelli, A.; Khalife, W. T.; Schmidt, T. M.; Young, V. B. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile -associated diarrhea J. Infect. Dis. 2008, 197 (3) 435-438
8. Musher, D. M.; Aslam, S.; Logan, N.; Nallacheru, S.; Bhaila, I.; Borchert, F.; Hamill, R. J. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole Clin. Infect. Dis. 2005, 40 (11) 1586-1590
9. Pépin, J.; Valiquette, L.; Gagnon, S.; Routhier, S.; Brazeau, I. Outcomes of Clostridium difficile -associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027 Am. J. Gastroenterol. 2007, 102 (12) 2781-2788
10. Zar, F. A.; Bakkanagari, S. R.; Moorthi, K. M.; Davis, M. B. A. comparison of vancomycin and metronidazole for the treatment of Clostridium difficile associated diarrhea, stratified by disease severity Clin. Infect. Dis. 2007, 45, 302-307
11. Louie, T. J.; Miller, M. A.; Mullane, K. M.; Weiss, K.; Lentnek, A.; Golan, Y.; Gorbach, S.; Sears, P.; Shue, Y. K.; OPT-80-003 Clinical Study Group Fidaxomicin versus vancomycin for Clostridium difficile infection N. Engl. J. Med. 2011, 364, 422-431
12. Yin, N.; He, Y.; Herradura, P.; Pearson, A.; Li, J.; Mascio, C. T.; Townsend-Howland, K.; Silverman, J.; Steenbergen, J.; Thorne, G.; Citron, D.; Van Praagh, A. D. G.; Mortin, L. I.; Pawliuk, R.; Oleson, R.; Keith, D.; Metcalf, C. In vitro and in vivo studies of a series of aliphatic tail-containing semi-synthetic lipopeptides against Clostridium difficile. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy Conference, Boston, MA, September 12-15, 2010, Abstract F1-1618.
13. Yin, N.; He, Y.; Herradura, P.; Pearson, A.; Li, J.; Mascio, C. T.; Townsend-Howland, K.; Silverman, J.; Steenbergen, J.; Thorne, G.; Citron, D.; Van Praagh, A. D. G.; Mortin, L. I.; Pawliuk, R.; Oleson, R.; Keith, D.; Metcalf, C. Structure activity relationship studies of aromatic tail containing lipopeptides leading to CB-183,315, a novel cyclic lipopeptide being developed for the treatment of Clostridium difficile infection. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy Conference, Boston, MA, September 12-15, 2010, Abstract F1-1612.
14. Miao, V.; Coëffet-Legal, M. F.; Brian, P.; Brost, R.; Penn, J.; Whiting, A.; Martin, S.; Ford, R.; Parr, I.; Bouchard, M.; Silva, C. J.; Wrigley, S. K.; Baltz, R. H. Daptomycin biosynthesis in Streptomyces roseosporus: cloning and analysis of the gene cluster and revision of peptide stereochemistry Microbiology 2005, 151 (Pt 5) 1507-1523
15. Hill, J.; Parr, I.; Morytko, M.; Sledlecki, J.; Yu, X. Y.; Silverman, J.; Keith, D.; Finn, J.; Christensen, D.; Lazarova, T.; Watson, A.; Zhang, Y. Preparation of lipopeptides as antibacterial agents. US 6911525 B2, 2005.
16. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard, 7th ed.; CLSI Document M11-A7; Clinical and Laboratory Standards Institute: 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2007.
17. Cloud, J.; Kelly, C. P. Update on Clostridium difficile associated disease Curr. Opin. Gastroenterol. 2007, 23, 4-9
18. Mascio, C. T.; Mortin, L. I.; Howland, K. T.; Van Praagh, A. D.; Zhang, S.; Arya, A.; Chuong, C. L.; Kang, C.; Li, T.; Silverman, J. A. In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile Antimicrob. Agents Chemother. 2012, 56 (10) 5023-5030
19. Baltz, R. H.; Miao, V.; Wrigley, S. K. Natural products to drugs: daptomycin and related lipopeptide antibiotics Nat. Prod. Rep. 2005, 22 (6) 717-741
20. Kahne, D.; Leimkuhler, C.; Lu, W.; Walsh, C. Glycopeptide and lipoglycopeptide antibiotics Chem. Rev. 2005, 105 (2) 425-448
21. Snydman, D. R.; Jacobus, N. V.; McDermott, L. A. Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens Antimicrob. Agents Chemother. 2012, 56 (6) 3448-3452
22. Citron, D. M.; Tyrrell, K. L.; Merriam, C. V.; Goldstein, E. J. In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species Antimicrob. Agents Chemother. 2012, 56 (3) 1613-1615